• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    12/15/22 4:36:34 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRTX alert in real time by email
    New Drug Application (NDA): 211988
    Company: HERON THERAPS INC
    • Email

    Products on NDA 211988

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    ZYNRELEF KIT BUPIVACAINE; MELOXICAM 60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Discontinued None Yes No
    ZYNRELEF KIT BUPIVACAINE; MELOXICAM 200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription None Yes Yes
    ZYNRELEF KIT BUPIVACAINE; MELOXICAM 300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Discontinued None Yes No
    ZYNRELEF KIT BUPIVACAINE; MELOXICAM 400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 211988

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/12/2021 ORIG-1 Approval Type 4 - New Combination PRIORITY Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211988Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211988Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    12/13/2022 SUPPL-10

    Label is not available on this site.

    12/08/2021 SUPPL-5 Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211988Orig1s005ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/211988Orig1s005.pdf

    Labels for NDA 211988

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    12/08/2021 SUPPL-5 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s005lbl.pdf
    05/12/2021 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s000lbl.pdf
    Get the next $HRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HRTX

    DatePrice TargetRatingAnalyst
    6/9/2025$6.00Buy
    H.C. Wainwright
    6/13/2024$7.00Buy
    Rodman & Renshaw
    4/23/2024$6.00Overweight
    CapitalOne
    3/13/2024$4.00 → $5.00Buy
    Needham
    More analyst ratings